SKCa Channels Blockage Increases the Expression of Adenosine A 2A Receptor in Jurkat Human T Cells

Abstract

Adenosine is a nucleoside displaying various biological effects via stimulation of four G-protein–coupled receptors, A₁, A_2A, A_2B, and A₃. Adenosine also modulates voltage-gated (Kv) and small conductance calcium-activated (SKCa) potassium channels. The effect of these potassium channels on the expression of adenosine receptors is poorly understood. We evaluated the action of BgK (a natural Kv channel blocker) and Lei-Dab7 (a synthetic SKCa channel blocker) on the expression of adenosine A_2A receptors (A_2AR) in Jurkat human T cells. We found that Lei-Dab7, but not BgK, increased the maximal binding value of the tritiated ligand ZM241385 to A_2AR in a dose-dependent manner (+45% at 5 nM; +70% at 50 nM as compared to control). These results were further confirmed by Western blotting using a specific monoclonal antibody to human A_2AR. The ligand affinity-related dissociation constant and A_2AR mRNA amount were not significantly modified by either drug. We suggest that modulation of SKCa channels can influence membrane expression of A_2AR and thus has a therapeutic potential.

Introduction

Adenosine is a ubiquitous nucleoside produced by ATP hydrolysis that is released by most cells into extracellular spaces where it binds G-protein–coupled receptors, namely, A₁, A_2A, A_2B, and A₃.^1–4 These receptors display various primary sequences and pharmacological properties.⁵ Adenosine modulates cAMP production of target cells⁶ and consequently the cAMP-dependent release of neurotransmitters.⁵ Activation of A₁ and A₃ subtypes inhibits cAMP production,⁷ but activation of A_2A and A_2B subtypes enhances cAMP production,^8,9 facilitating the cAMP-dependent neurotransmitter discharge.¹⁰ Although adenosine and adenosine receptor agonists inhibit voltage-activated calcium channels (especially N and L types) of smooth muscle cells through the βγ G-protein complex leading to vasodilation and hypotension,^11–15 they also modulate potassium channels.^16–20 These potassium channels are subdivided into voltage-gated (Kv), calcium-activated (KCa), inward rectifier (including those that are ATP sensitive, KATP), and two-pore channels.^21–24 KCa channels are further classified as big (BKCa), intermediate (IKCa), and small (SKCa) conductance channels.^25–27 These channels are activated by increased cytoplasmic concentration of Ca²⁺,^28–33 BKCa channels also being voltage sensitive. SKCa channels are subdivided into three classes (SKCa1–3).^34,35 Most potassium channel subtypes are modulated by adenosine through activation of adenosine receptors.^5,15 In contrast, vasodilation of arteries induced by CGS21680, an adenosine A_2A receptor (A_2AR) agonist,³⁶ is inhibited by a cocktail of nonspecific potassium channel blockers,³⁷ and smooth cell relaxation induced by activation of A_2AR occurs partly through the modulation of KCa channels.^38,39 Furthermore, iberiotoxin, an Eastern Indian red scorpion (Buthus tamulus) toxin, which is a blocker of BKCa channels,^40,41 attenuated the release of nitric oxide by endothelial cells that occurs during A_2AR activation, suggesting that both BKCa and SKCa are coupled to A_2AR.⁴² CGS21680 also induces enhanced mRNA expression of Kv1.3 and increased production of Kv protein, while the A_2AR antagonist ZM241385 inhibits these effects.⁴³ Among SK channels, SKCa1 and SKCa2 are involved in the physiological effects of CGS21680.⁴⁴ Numerous studies dealing with the consequences of A_2AR activation on potassium channel modulation have been reported, but little is known about the influence of potassium channels modulation on the expression of A_2AR. The aim of this study was thus to evaluate the influence of Kv and SKCa channel blockers on A_2AR expression in a human T-cell line as measured by ligand binding saturation curves, Western blots and mRNA amount.

Materials and Methods

Materials

BgK, a potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels, was purchased from Latoxan^®, (Valence, France). Caffeine was from Sigma-Aldrich (Saint Quentin Fallavier, France). [³H]-ZM241385 was from Tocris Cookson (Bristol, United Kingdom; 23.5 mCi/mmol), and ZM241385 was from Fischer Bioblock Scientific (Ilkirsch, France). Lei-Dab7 was synthesized by the stepwise solid-phase method⁴⁵ by using a peptide synthesizer (Model 433A, Applied Biosystems Inc., Foster City, CA). The side-chain protecting groups used for trifunctional residues were: 2,2,5,7,8-pentamethylchromane-6-sulfonyl for Arg and homoarginine; tert-butyloxycarbonyl for Orn, Lys, and homolysine; and 1-(4,4-dimethyl-2,6-dioxocyclohex-1-yliden)-3-methylbutyl for Dab and diaminopropionic acid (Dapa). The reduced peptides were stirred under air at 1 mM in 0.2 M Tris-HCl buffer, pH 8.3 for 48 h at 25°C to allow folding/oxidation. The folded/oxidized toxins and their structural analogs were purified to homogeneity by reverse-phase high-pressure liquid chromatography onto a C-18 ODS Aquapore column (PerkinElmer Life Sciences, Waltham, MA).

Cell membrane preparation

The Jurkat human T-cell line was cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum and 1% glutamine at 37°C with 5% CO₂ at about 1×10⁶ cells/mL. Cells were cultured for 24 h alone and in the presence of BgK or Lei-Dab7 (both at 1, 5, and 50 nM) and caffeine (at 50 and 300 nM). Cells were centrifuged, and 9×10⁹ cells were suspended in 4.5 mL of binding buffer (50 mM Tris-HCl, 10 mM MgCl₂, pH 7.4), homogenized for 30 s using an Ultra Turrax (Staufen, Germany), and immediately used in binding assay. Protein concentration was determined using a Beckman Synchron LX apparatus (Villepinte, France).

Binding assay

The methodology described by Varani et al.⁴⁶ was used with some modifications:⁴⁷ saturation binding experiments were performed in triplicate, using the selective A_2AR ligand [³H]-ZM241385, by incubating 200 μL of cell membrane homogenates for 90 min at 4°C with increasing concentrations of tritiated ligand (0.5–6 nM). Bound and free signals were separated using vacuum filtration of the sample through Whatman GF/C glass-fiber filters. Cold binding buffer (1 mL) was added to the sample before filtering. The filter was extensively washed and the signal associated with the filter was determined using a Beckman LS-1800 liquid scintillation spectrometer. A weighted, nonlinear, least-square curve-fitting program, Graph Pad Prism (Graph Pad Software Inc., San Diego, CA) was used for maximal binding (Bmax) and dissociation constant (K_D) determination. Nonspecific binding of [³H]-ZM241385 was measured in the presence of an excess (10 μM) of unlabeled ligand.

Western blotting

Cells (0.5×10⁶) were solubilized with 30 μL of 62.5 mM Tris-HCl buffer, pH 8.3, containing 2% sodium dodecyl sulfate, 10% glycerol, 0.01% bromophenol blue, and 5% mercaptoethanol. Solubilizates were sonicated for 10 min at 47 kHz and loaded onto a 12% acrylamide, 60 mm×90 mm, 1.5-mm-thick minigel. Cell proteins were submitted to standard electrophoresis procedure. Separated proteins in the gel were directly electrotransferred onto a 0.45-μm polyvinylidene difluoride membrane. Blotted membrane was saturated with nonfat dried milk and incubated with Adonis, a mouse monoclonal antibody to human A_2AR.⁴⁸ Anti-glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH) mouse monoclonal antibody (Clone GAPDH-71.1, Sigma, St. Louis, MO) was added to Adonis as loading control for normalizing blot results to GAPDH. Blots were visualized by horseradish peroxidase–labeled anti-mouse antibodies and enhanced chemiluminescence substrate (SuperSignal West Femto, Pierce Biotechnology, Rockford, IL) using a Kodak Image Station 440CF (Eastman Kodak Company, Rochester, NY). The staining intensities of the bands were measured by densitometry using ImageJ 1.42q software (National Institutes of Health, Bethesda, MD) and results were expressed as the pixel ratio of the A_2AR/GAPDH bands.

Quantification of A_2AR mRNA

Total RNA from Jurkat cells was extracted with the MagAttract RNA tissue Mini M48 kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations (Bio-Robot M48). cDNA was prepared from 250 ng of total RNA. Real-time polymerase chain reaction was performed with a Light-Cycler (Roche, Neuilly sur Seine, France) using the Light-Cycler FastStart DNA Master plus SYBR green I kit. The 18S rRNA primers were 5′-GGT-GAC-GCG-GAA-TCA-GG-3′ (forward) and 5′-GCT-GCT-GGC-ACC-AGA-C-3′ (reverse), generating a 218-bp DNA fragment. The A_2AR primers were 5′-TCC-CAT-GCT-AGG-TTG-GAA-CA-3′ (forward) and 5′-GGA-AGA-TCC-GCA-AAT-AGA-CAC-3′ (reverse), generating a 191-bp DNA fragment. The amount of mRNA encoding A_2AR was expressed in arbitrary units (AU) defined as the amount ratio of A_2AR mRNA/18S rRNA.

Statistical analysis

A two-way analysis of variance (ANOVA) was used for intergroup comparisons. A p-value<0.05 was considered to be significant.

Results and Discussion

SKCa channels are expressed in various cells of the central nervous^49,50 and cardiovascular systems^51,52 where they play a key role in all excitable cells. SKCa channels are involved in the “after hyperpolarization process,”⁵³ a period in which the membrane potential is negative to the normal resting potential and then slowly returns to baseline. The activation of SKCa channels causes membrane hyperpolarization, which protects excitable cells against repetitive action potential.⁵⁴ SKCa channels are also expressed in hematopoietic cells, where they modulate reactive oxygen species by neutrophils.⁵⁵ In lymphocytes, several types of potassium channels (especially Kv1.3 and IKCa1) were reported with particular roles in mitogen- and antigen-specific proliferation, cell volume regulation, and apoptosis.^56,57

Lei-Dab7 is a synthetic analogue of Leiurus quinquestriatus scorpion toxin, which is a highly selective inhibitor of SKCa2.⁵⁸ It was previously reported that Lei-Dab7 decreases the analgesic effects of CGS21680, an A_2AR agonist, in a dose-dependent manner.⁴⁴ This suggests that SKCa2 mediates, at least in part, the biological properties of CGS21680. In order to determine the impact of potassium channel blockers on the amount of and the ligand affinity for A_2AR expressed on the cell membrane, Bmax and K_D values were estimated, respectively, from saturation curves of [³H]-ZM241385 binding to Jurkat T cells. Representative dose–response curves performed with and without 50 nM of Lei-Dab7 (a SKCa channel blocker), BgK (a Kv channel blocker), and caffeine (used here as a positive control) are shown in Figure 1. Lei-Dab7 treatment increased the Bmax value of A_2AR in a dose-dependent manner (+45% at 5 nM and +70% at 50 nM as compared to control), BgK did not significantly modulate Bmax values at the concentrations tested, and caffeine increased Bmax values by 77% and 104%, as compared to controls, at 50 and 300 nM, respectively (Fig. 2A). The specificity of these results was further confirmed by Western blotting using Adonis, a specific monoclonal antibody directed to the second extracellular loop of the human A_2AR.⁴⁸ Figure 2B shows that Adonis revealed similar expressions of A_2AR in cells incubated with or without 50 nM BgK (mean pixels ratio of A_2AR/GAPDH bands±SD of triplicates: 0.13±0.08 and 0.09±0.05, respectively) and higher expressions of A_2AR in cells incubated with 50 nM Lei-Dad7 and caffeine (0.63±0.11 and 0.76±0.16, respectively). The mean K_D value (±SD of triplicates) of ZM241385 for A_2AR in the presence of 50 nM of BgK, Lei-Dab7, and caffeine was 5.2±0.9, 3.2±2.2, and 6.3±2.7 nM, respectively, as compared to control (without drug): 3.7±1.1 nM. The amount of mRNA encoding A_2AR in the presence of 50 nM of BgK, Lei-Dab7, and caffeine was 17±0.9, 17.2±0.7, and 18±0.9 AU, respectively, as compared to control (17.6±0.6 AU). The statistical analysis of these results indicated that both the K_D value of ZM241385 for A_2AR and the amount of mRNA encoding A_2AR were not significantly modified by Lei-Dab7, BgK, and caffeine treatment.

FIG. 1.

Representative dose-response curves of [³H]-ZM241385 binding to adenosine A_2A receptor (A_2AR) of Jurkat T-cell membrane. Cells cultured without drug (A) and cells cultured with 50 nM of Lei-Dab7 (B), caffeine (C), and BgK (D). Data are means±SD of triplicates. Scatchard plots (ratio of concentrations of bound ligand to unbound ligand versus the bound ligand concentration) for dissociation constant (K_D) determination are inserted in graphs.

FIG. 2.

(A) Dose–response bar-chart of BgK, Lei-Dab7, and caffeine for A_2AR expression (maximal binding [Bmax]) in Jurkat T cells. Data are means±SD of triplicates. Bmax values were measured using [³H]-ZM241385. *p<0.05 as compared to controls and BgK; **p<0.05 as compared to 5 nM; ***p<0.05 as compared to 50 nM. (B) Representative Western blots of Adonis binding to Jurkat T cells previously incubated with or without 50 nM of BgK, Lei-Dab7, and caffeine. GADPH served as loading control. The A_2AR and GAPDH bands migrated to 45- and 37-kDa regions, respectively, and were analyzed by density reading.

Here, we found that inhibition of SKCa2 enhances A_2AR expression at the cell membrane in a dose-dependent manner. This increase mimics those obtained using caffeine, which is known to induce an up-regulation of A_2AR.^48,59 The specificity of our results was confirmed by using BgK, which blocks Kv1 potassium channels^60,61 and did not modify A_2AR expression even at high (50 nM) levels. The A_2AR increase we observed did not result from increased A_2AR mRNA cellular expression; however, a lack of change in mRNA expression did not exclude an increase in A_2AR protein synthesis. Also, it was previously reported that glibenclamide, a KATP channel blocker, modifies the affinity of CGS21680 for A_2AR.³⁸ Here, the potassium channel blockers Lei-Dab7 and BgK, like caffeine, did not change the K_D of ZM241385 for A_2AR and, consequently, did not affect the A_2AR ligand affinity.

A_2AR are coupled to G-proteins to activate adenyl cyclase, resulting in increased cAMP production that, in turn, can activate protein kinase A (PKA)⁶² and stimulate potassium channels.⁶³ This signaling pathway was reported in vasodilatation of rat preglomerular microvessels⁶⁴ to be coupled to a release of epoxyeicosatrienoic acids, which were also reported to have cardioprotective effects by modulation of mitochondrial ion channels like KATP and signaling through phosphoinositide 3-kinase pathways.⁶⁵ In immune cells, A_2AR-mediated activation of cAMP-dependent PKA induces phosphorylation of cAMP-responsive element-binding proteins, which activates numerous genes transcription via their promoters and consequently alters cell growth and cytokines expression.⁶⁶ Another downstream target of PKA is the L-type calcium channel that allows Ca²⁺ to enter into T cells for their activation and function.⁶⁷ Alternately, in PC12 cells, prolonged A_2AR stimulation activates novel protein kinase C (PKC) through a pertussis toxin–sensitive G-protein and phosphorylates and suppresses the type VI adenyl cyclase, which causes negative feedback regulation of the cAMP signal induced by the A_2AR.⁶⁸ The signaling pathways of the A_2AR appear complex and interconnected. It is not surprising that A_2AR interferes with potassium channels and calcium cellular fluxes and vice versa. T-cell activation requires sustained calcium signaling provided by a concerted interaction between potassium channels and the calcium release-activated calcium channels.⁶⁹ Thus, by acting via A_2AR to inhibit stimulated T cells, potassium channels can be viewed as potential targets for immunosuppression.^70,71

The present results suggest that the blockade of SKCa channels in Jurkat T cells may influence the membrane expression of A_2AR by a mechanism that remains to be revealed. We hypothesize that blockage of SKCa channels increases intracellular calcium levels ([Ca²⁺]i), inducing activation of calcium-dependent protein kinases that, in turn, increase the expression of cell-membrane proteins such as A_2AR. The modulation in A_2AR expression induced by SKCa channels may help to fine-tune the immunosuppressive signaling in T cells and, in this respect, has an interesting therapeutic potential. However, this mechanism needs to be confirmed by further functional investigations in immune as well as excitable neuronal and cardiac cells.

Footnotes

Acknowledgments

Y. By is a recipient of grant from the Assistance Publique, Hôpitaux de Marseille, France.

References

Kataoka

, Baquero

, Yang

, Shultz

et al. A2BR adenosine receptor modulates sweet taste in circumvallate taste buds. PLoS One, 2012; 7:e29728.

Murphree

, Linden

. Adenosine receptors. Encyclopedia of Biological Chemistry, 1 Lennarz

, Lane

. Academic Press: London, 34–39. 2004.

Ohana

, Bar-Yehuda

, Barer

et al. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol., 2001; 186:19–23.

Fredholm

, Ijzerman

, Jacobson

et al. Nomenclature and classification of adenosine receptors. Pharmacol Rev., 2001; 53:527–552.

Ralevic

, Burnstock

. Receptors for purines and pyrimidines. Pharmacol Rev., 1998; 50:413–492.

Chavez-Valdez

, Wills-Karp

, Ahlawat

et al. Caffeine modulates TNF-α production by cord blood monocytes: the role of adenosine receptors. Pediatr Res., 2009; 65:203–208.

Klinger

, Freissmuth

, Nanoff

. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal., 2002; 14:99–108.

Lokshin

, Raskovalova

, Huang

et al. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res., 2006; 66:7758–7765.

Gessi

, Varani

, Merighi

et al. Adenosine and lymphocyte regulation. Purinergic Signal., 2007; 3:109–116.

10.

Sebastiao

, Ribeiro

. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol., 1996; 48:167–189.

11.

Murphy

, Gerzanich

, Zhou

et al. Adenosine A2a receptor down-regulates cerebral smooth muscle L-type Ca2+ channel activity via protein tyrosine phosphatase, not cAMP-dependent protein kinase. Mol Pharmacol., 2003; 64:640–649.

12.

Coney

, Marshall

. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. J Physiol., 1998; 509:507–518.

13.

Shin

, Park

, Hong

. Implication of adenosine A2A receptors in hypotension induced vasodilation and cerebral blood flow autoregulation in rat pial arteries. Life Sci., 2000; 67:1435–1445.

14.

Ngai

, Coyne

, Meno

et al. Receptor subtypes mediating adenosine induced dilation of cerebral arterioles. Am J Physiol., 2001; 280:H2329–H2335.

15.

Belardinelli

, Shryock

, Song

et al. Ionic basis of the electrophysiological actions of adenosine in cardiomyocytes. FASEB J., 1995; 9:359–365.

16.

Marshall

, Thomas

, Turner

. A link between adenosine, ATP sensitive K+ channels, potassium and muscle vasodilatation in the rat in systemic hypoxia. J Physiol., 1993; 472:1–9.

17.

Dart

, Standen

. Adenosine activated potassium current in smooth muscle cells isolated from the pig coronary artery. J Physiol., 1993; 471:767–786.

18.

Hadjkaddour

, Michel

, Laurent

et al. Smooth muscle relaxant activity of A1- and A2-selective adenosine receptor agonists in guinea pig trachea: involvement of potassium channels. Fund Clin Pharmacol., 1996; 10:269–277.

19.

Sabates

, Pigott

, Choe

et al. Adrenomedullin mediates coronary vasodilation through adenosine receptors and KATP channels. J Surgical Res., 1997; 67:163–168.

20.

Sheridan

, McIntyre

, Meldrum

et al. KATP channels contribute to β- and adenosine receptor-mediated pulmonary vasorelaxation. Am J Phys., 1997; 273:950–956.

21.

Alexander

SPH

, Mathie

, Peters

. Guide to receptors and channels. Br J Pharmacol., 2008; 153:S1–209.

22.

Ford

, Stevens

, Treheme

et al. Potassium channels: gene therapeutic relevance, high throughput screening technologies and drug discovery. Prog Drug Res., 2002; 58:133–168.

23.

Lesage

, Lazdunski

. Molecular and functional properties of two-pore domain potassium channels. Am J Physiol., 2000; 279:F793–F801.

24.

Vergara

, Latorre

, Marrion

et al. Calcium-activated potassium channels. Curr Opin Neurobiol., 1998; 8:321–329.

25.

Gardos

. The function of calcium in the potassium permeability of human erythrocytes. Biochem Biophys Acta., 1958; 30:653–654.

26.

Blatz

, Magleby

. Calcium-activated potassium channels. Trends Neurosci., 1987; 10:463–467.

27.

Sah

. Ca2+-activated K+ currents in neurones: types, physiological roles and modulation. Trends Neurosci., 1996; 19:150–154.

28.

Busse

, Fichtner

, Luckhoff

et al. Hyperpolarization and increased free calcium in acetylcholine-stimulated endothelial cells. Am J Physiol., 1988; 255:H965–969.

29.

Cheung

, Chen

. Calcium activation of hyperpolarization response to acetylcholine in coronary endothelial cells. J Cardiovasc Pharmacol., 1992; 20:S120–123.

30.

Johns

, Freay

, Adams

et al. Role of calcium in the activation of endothelial cells. J Cardiovasc Pharmacol., 1988; 12:S119–123.

31.

Kamouchi

, Van Den Brent

, Eggermont

et al. Modulation of inwardly rectifying potassium channels in cultured bovine pulmonary artery endothelial cells. J Physiol., 1997; 504:545–556.

32.

Luckhoff

, Busse

. Activators of potassium channels enhance calcium influx into endothelial cells as a consequence of potassium currents. Arch Pharmacol., 1990; 342:94–99.

33.

Luckhoff

, Busse

. Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflugers Arch., 1990; 416:305–311.

34.

, Tuteja

, Zhang

et al. Molecular identification and functional roles of a Ca(2+) activated K+ channel in human and mouse hearts. J Biol Chem., 2003; 278:49085–49094.

35.

Tuteja

, Xu

, Timofeyev

et al. Differential expression of small-conductance Ca2+ activated K+ channels SK1, SK2 and SK3 in mouse atrial and ventricular myocytes. Am J Physiol Heart Circ Physiol., 2005; 289:H2714–H2723.

36.

Hutchison

, Webb

, Oei

et al. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther., 1989; 251:47–55.

37.

Prior

, Yates

, Beech

. Role of K+ channels in A2A adenosine receptor-mediated dilation of the pressurized renal arcuate artery. Br J Pharmacol., 1999; 26:494–500.

38.

Olanrewaju

, Marais

, Mustafa

. Modulation of A2A adenosine receptors by K+ATP channels in bovine brain striatal membranes. Cell Biol Inter., 1999; 7:519–522.

39.

Haynes

. A(2A) adenosine receptor mediated potassium channel activation in rat epididymal smooth muscle. Br J Pharmacol., 2000; 130:685–691.

40.

Galvez

, Gimenez-Gallego

, Reuben

et al. Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem., 1990; 265:11083–11090.

41.

Gribkoff

, Starrett

Jr , Dworetzky

. The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv Pharmacol., 1997; 37:319–348.

42.

Ray

, Marshall

. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J Physiol., 2005; 570:85–96.

43.

Kust

, Biber

, van Calker

et al. Regulation of K+ channel mRNA expression by stimulation of adenosine A2A-receptors in cultured rat microglia. Glia., 1999; 25:120–130.

44.

Regaya

, Pham

, Andreotti

et al. Small conductance calcium-activated K+ channels, SkCa, but not voltage-gated K+(Kv) channels, are implicated in the antinociception induced by CGS21680, a A2A adenosine receptor agonist. Life Sci., 2004; 76:367–377.

45.

Merrifield

. Solid phase synthesis. Science, 1986; 232:341.

46.

Varani

, Laghi-Pasini

, Camurri

et al. Changes of peripheral A2A adenosine receptors in chronic failure and cardiac transplantation. FASEB J., 2003; 17:280–282.

47.

Carrega

, Saadjian

, Mercier

et al. Increased expression of adenosine A2A receptors in patients with spontaneous and head-up tilt induced syncope. Heart Rhythm., 2007; 4:870–876.

48.

, Durand-Gorde

, Condo

et al. Production of an agonist-like monoclonal antibody to the human A2A receptor of adenosine for clinical use. Mol Immunol., 2009; 46:400–405.

49.

Liegeois

, Mercier

, Graukich

et al. Modulation of small conductance calcium-activate potassium (SK channels): a new challenge in medicinal chemistry. Curr Med Chem., 2003; 10:625–647.

50.

Blank

, Nijholt

, Kye

et al. Small conductance Ca2+-activated K+ channels as targets of CNS drug development. Curr Drug Targets CNS Neurol Disord., 2004; 3:161–167.

51.

Neylon

, Lang

, Fu

et al. Molecular cloning and characterization of the intermediate-conductance Ca(2+)-activated K(+) channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circ Res., 1999; 85:e33–e43.

52.

Pribmow

, Johnson-Pais

, Bond

et al. Skeletal muscle and small-conductance calcium-activated potassium channels. Muscle Nerve., 1999; 22:742–750.

53.

Kim

, Hoffman

. Potassium channels: newly found players in synaptic plasticity. Neuroscientist, 2008; 14:276–286.

54.

Bond

, Maylie

, Adelman

. Small-conductance calcium-activated potassium channels. Ann NY Acad Sci., 1999; 868:370–378.

55.

Fay

, Qian

, Jan

et al. SK channels mediate NADPH oxidase-independent reactive oxygen species production and apoptosis in granulocytes. Proc Natl Acad Sci USA, 2006; 46:17548–17553.

56.

Panyi

, Varga

, Gáspár

. Ion channels and lymphocyte activation. Immunol Lett., 2004; 92:55–66.

57.

Cahalan

, Wulff

, Chandy

. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol., 2001; 21:235–252.

58.

Shakkottai

, Regaya

, Wulff

et al. Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2. J Biol Chem., 2001; 276:43145–43151.

59.

Varani

, Portaluppi

, Gessi

et al. Dose and time effects of caffeine intake on human platelet adenosine A (2A) receptors: functional and biochemical aspects. Circulation, 2000; 102:285–289.

60.

Alessandri-Haber

, Lecoq

, Gasparini

et al. Mapping the functional anatomy of BgK on Kv1.1, Kv1.2, and Kv1.3 clues to design analogs with enhanced selectivity. J Biol Chem., 1999; 50:35653–35661.

61.

Rangaraju

, Khoo

, Feng

et al. Potassium channel modulation by a toxin domain in matrix metalloprotease 23. J Biol Chem., 2009; 285:9124–9136.

62.

Fredholm

, Arslan

, Halldner

et al. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol., 2000; 362:364–374.

63.

Rump

, Jabbari-T

, von Kügelgen

et al. Adenosine mediates nitric-oxide-independent renal vasodilation by activation of A2A receptors. J Hypertens., 1999; 17:1987–1993.

64.

Carroll

, Doumad

, Li

et al. Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol., 2006; 291:F155–161.

65.

Batchu

, Lee

, Qadhi

et al. Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br J Pharmacol., 2011; 162:897–907.

66.

Fredholm

, Chern

, Franco

et al. Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol., 2007; 83:263–276.

67.

Matza

, Flavell

. Roles of Ca(v) channels and AHNAK1 in T cells: the beauty and the beast. Immunol Rev., 2009; 231:257–264.

68.

Lai

, Yang

, Messing

et al. Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response. J Biol Chem., 1997; 272:4970–4977.

69.

Panyi

, Vámosi

, Bodnár

et al. Looking through ion channels: recharged concepts in T-cell signaling. Trends Immunol., 2004; 25:565–569.

70.

Chandy

, Wulff

, Beeton

et al. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci., 2004; 25:280–289.

71.

Huang

, Apasov

, Koshiba

et al. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood, 1997; 90:1600–1610.

SKCa Channels Blockage Increases the Expression of Adenosine A 2A Receptor in Jurkat Human T Cells

Abstract

Introduction

Materials and Methods

Materials

Cell membrane preparation

Binding assay

Western blotting

Quantification of A2AR mRNA

Statistical analysis

Results and Discussion

Footnotes

Acknowledgments

References

Quantification of A_2AR mRNA